Induction of CD4+CD25+Foxp3+ regulatory t cell response by glatiramer acetate in type 1 diabetes

Cell Research

Volumn 19, Issue 5, 2009, Pages 574-583

  Cui, Guoliang ^a   Zhang, Yuebo ^a   Gong, Zhenwei ^a   Zhang, Jingwu Z ^b   Zang, Ying Qin ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Foxp3; Glatiramer acetate; Regulatory T cell; Type 1 diabetes

Indexed keywords

MUS;

ANTIDIABETIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GLATIRAMER; INTERLEUKIN 4; PEPTIDE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; REGULATORY T LYMPHOCYTE; UPREGULATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-4; MICE; MICE, INBRED NOD; PEPTIDES; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 67649132737     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2009.12     Document Type: Article

References (34)

1. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317:408-414.
2. Teitelbaum D, Milo R, Arnon R, Sela M. Synthetic copolymer 1 inhibits human T-cell lines specifc for myelin basic protein. Proc Natl Acad Sci USA 1992; 89:137-141.
3. Canter MB. Reflections on receiving an award. Am Psychol 2000; 55:1304-1311.
4. Zhang M, Chan CC, Vistica B, Hung V, Wiggert B, Gery I. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol 2000; 103:189-194.
5. Arnon R, Aharoni R. Mechanism of action of glatiramer ac- etate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA 2004; 101 (Suppl 2):14593-14598.
6. Horani A, Muhanna N, Pappo O, et al. Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of ex- perimental hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 292:G628-G638.
7. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci USA 1994; 91:4872-4876.
8. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003; 170:4483-4488.
9. Weber MS, Prod'homme T, Youssef S, et al. Type II monocy- tes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13:935-943.
10. Billiard F, Litvinova E, Saadoun D, et al. Regulatory and ef- fector T cell activation levels are prime determinants of in vivo immune regulation. J Immunol 2006; 177:2167-2174.
11. Piccirillo CA, Tritt M, Sgouroudis E, Albanese A, Pyzik M, Hay V. Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice. Ann N Y Acad Sci 2005; 1051:72-87.
12. Vukmanovic-Stejic M, Zhang Y, Cook JE, et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006; 116:2423-2433.
13. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfn, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27:68-73.
14. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-1061.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-336.
16. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfn in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4:337-342.
17. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005; 102:6449-6454.
18. Jee Y, Piao WH, Liu R, et al. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol 2007; 125:34-42.
19. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85:291-297.
20. Liu E, Eisenbarth GS. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol Metab Clin North Am 2002; 31:391-410, vii-viii.
21. Weiner HL. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 1999; 96:3333- 3335.
22. Brode S, Raine T, Zaccone P, Cooke A. Cyclophosphamide- induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2006; 177:6603-6612.
23. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimu- lation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-440.
24. Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003; 171:4040-4047.
25. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 2004; 34:2480-2488.
26. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004; 172:6519-6523.
27. Thornton AM, Piccirillo CA, Shevach EM. Activation require- ments for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 2004; 34:366-376.
28. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-1886.
29. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phe- notype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004; 172:5149-5153.
30. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005; 201:1061- 1067.
31. Wang Z, Hong J, Sun W, et al. Role of IFN-gamma in induc- tion of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest 2006; 116:2434-2441.
32. Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL- 13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol 2005; 175:6107-6116.
33. Maerten P, Shen C, Bullens DM, et al. Effects of interleukin 4 on CD25+CD4+ regulatory T cell function. J Autoimmun 2005; 25:112-120.
34. Hamilton-Williams EE, Palmer SE, Charlton B, Slattery RM. Beta cell MHC class I is a late requirement for diabetes. Proc Natl Acad Sci USA 2003; 100:6688-6693.